Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    Online

    What is this Study about?

    Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The overall aim of the current study is to evaluate a newly developed app that focuses on providing stress-management strategies for family caregivers of people living with dementia. Findings from the study of an app that aims to address the stressors associated with caregiving has the potential to improve the quality of life of caregivers of people living with dementia.

    Eligibility Criteria

    - Providing informal and unpaid care (e.g., spouses, children) for people living with dementia

    - Providing primary care (i.e., most of the care or equally shares the care with another individual such as a mother or sibling) for the person living with dementia

    - Own a smartphone (e.g., iPhone, Android)

    - Not currently using a mobile app created for caregivers

    - Ability to speak English

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

    Eligibility Criteria

    Age 50 - 85
    Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.

    Eligibility Criteria

    60+
    Diagnosis of Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Clinical Trial
    Online

    What is this Study about?

    The goal of the proposed SYNERGIC-2 TRIAL (SYNchronizing Exercises, and Remedies to GaIn Cognition@home) is to evaluate cognitive improvements from personalized multidomain interventions that target multiple dementia risk factors delivered at home to older adults with Mild Cognitive Impairment (MCI).

    Eligibility Criteria

    - Aged 60-85 years.

    - Concerned about memory or thinking problems.

    - Have access to internet at home.

    - Ability to speak English.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

    Eligibility Criteria

    You are eligible to participate if you meet the following criteria:

    • Age ≥ 55; females must be post-menopausal

    • DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)

    • sMMSE ≤ 24

    • Clinically significant agitation based on IPA definition

    • Stable cognition-enhancing medication for at least 3 months prior to study enrolment

    • Availability of a caregiver to accompany participant to study visits and to participate in the study

    • Ability to speak English

    Recruitment End Date

  • Clinical Trial
    Online & In-Person

    What is this Study about?

    To examine the effects of a stress management program on well-being, stress, and cognition in family caregivers of someone with dementia or a related neurodegenerative disorder. We will be recruiting participants from 2023 - 2027.

    Eligibility Criteria

    - are a primary family caregiver of a person with dementia or a related neurodegenerative disorder.

    - have access to a computer with high-speed internet; and feel comfortable using email and Zoom (a secure online meeting platform).

    - have a video camera on your device. To ensure safety of participants during the program sessions, it is important that participants turn on their video camera. Keeping the video camera on is also important to build trust within the group sessions and when interacting with the researchers.

    - are willing to be randomised to one of 3 groups, even if it is not your preferred group.

    - are able to commit to a synchronous 8-week online group-based program (described below) and complete daily prescribed daily home practices.

    - are able to commit to three assessment sessions: one baseline assessment, one post-program assessment, one 12-month follow-up assessment.

    - agree to audio recording of interview sessions and portions of the assessment that require accurate verbal data collection.

    - are able to provide blood samples, potentially after a 12-hour fast.

    - are able to travel to a LifeLabs clinic for biomarker collection.

    - agree to refrain from participating in new studies or programs during the 8-week study session.

    - meet the screening criteria during the pre-screening interview.

    - ability to speak English.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia

    Eligibility Criteria

    Age 50 - 80
    Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease

    Recruitment End Date